000 -LEADER |
fixed length control field |
03177nam a22005295i 4500 |
001 - CONTROL NUMBER |
control field |
978-3-7643-7418-1 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20161121230709.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
100301s2006 sz | s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9783764374181 |
-- |
978-3-7643-7418-1 |
024 7# - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1007/3-7643-7418-7 |
Source of number or code |
doi |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
RC261-271 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJCL |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED062000 |
Source |
bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
614.5999 |
Edition number |
23 |
245 10 - TITLE STATEMENT |
Title |
Aromatase Inhibitors |
Medium |
[electronic resource] / |
Statement of responsibility, etc. |
edited by Barrington J.A. Furr. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Basel : |
Name of producer, publisher, distributor, manufacturer |
Birkh�user Basel, |
Date of production, publication, distribution, manufacture, or copyright notice |
2006. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
IX, 182 p. 30 illus. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda1 |
490 ## - SERIES STATEMENT |
Series statement |
Milestones in Drug Therapy MDT0 |
505 ## - FORMATTED CONTENTS NOTE |
Formatted contents note |
Background and development of aromatase inhibitors -- Aromatase inhibitors and models for breast cancer -- Clinical pharmacology of aromatase inhibitors -- Clinical studies with exemestane -- Clinical studies with letrozole -- Clinical studies with anastrozole -- The third-generation aromatase inhibitors: a clinical overview -- Lessons from the ArKO mouse -- Possible additional therapeutic uses of aromatase inhibitors. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy. |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Medicine. |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cancer research. |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Pharmacology. |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Internal medicine. |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Oncology. |
650 0# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cell biology.1 |
650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Biomedicine.2 |
650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cancer Research.2 |
650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Pharmacology/Toxicology.2 |
650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Internal Medicine.2 |
650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Oncology.2 |
650 4# - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cell Biology.1 |
700 ## - ADDED ENTRY--PERSONAL NAME |
Personal name |
Furr, Barrington J.A. |
Relator term |
editor.2 |
710 ## - ADDED ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
SpringerLink (Online service)0 |
773 ## - HOST ITEM ENTRY |
Title |
Springer eBooks0 |
776 8# - ADDITIONAL PHYSICAL FORM ENTRY |
Relationship information |
Printed edition: |
International Standard Book Number |
9783764371999 |
830 0# - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Milestones in Drug Therapy MDT4 |
856 0# - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
http://dx.doi.org/10.1007/3-7643-7418-7 |
912 ## - |
-- |
ZDB-2-SBL |